BHVN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.180

-36.21%

-1.247

-42.53%

-1.035

-46.65%

Estimates Revision

The market is revising Downward the revenue expectations for Biohaven Ltd. (BHVN) for FY2025, with the revenue forecasts being adjusted by -49.46% over the past three months. During the same period, the stock price has changed by -17.90%.

Revenue Estimates for FY2025

Revise Downward

-49.46%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-13.27%

In Past 3 Month

Stock Price

Go Down

-17.90%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is 16.82 USD with a low forecast of 9.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

5 Hold

0 Sell

Moderate Buy

Current: 11.280

Low

9.00

Averages

16.82

High

30.00

Current: 11.280

Low

9.00

Averages

16.82

High

30.00

H.C. Wainwright

Buy

Neutral

downgrade

$30 -> $11

2025-12-03

Reason

H.C. Wainwright

Price Target

$30 -> $11

2025-12-03

downgrade

Buy

Neutral

Reason

H.C. Wainwright downgraded Biohaven to Neutral from Buy with a price target of $11, down from $30. The company reduced operating expenses and raised additional funding, "but now needs clear wins to keep the pipeline moving," the analyst tells investors in a research note. The firm sees a low likelihood that opakalim's Phase 3 data will exceed, or even match, azetukalner's efficacy. It downgrades the shares seeing "fewer ways to win."

UBS

Buy -> Neutral

downgrade

$26 -> $11

2025-11-26

Reason

UBS

Price Target

$26 -> $11

2025-11-26

downgrade

Buy -> Neutral

Reason

UBS downgraded Biohaven to Neutral from Buy with a price target of $11, down from $26. The firm says the company's "multiple" research and development and regulatory setbacks have lowered confidence on the viability of its remaining pipeline programs. Most of the immediate value in Biohaven's pipeline comes from Kv7, but the company is two years behind competitor Xenon in the primary indication, the analyst tells investors in a research note. UBS sees a balanced risk/reward for the shares into the upcoming pipeline catalysts.

JPMorgan

Overweight -> NULL

downgrade

$47 -> $15

2025-11-20

Reason

JPMorgan

Price Target

$47 -> $15

2025-11-20

downgrade

Overweight -> NULL

Reason

JPMorgan lowered the firm's price target on Biohaven to $15 from $47 and keeps an Overweight rating on the shares. The firm finds it "prudent" for Biohaven to undertake cost optimization efforts and restructure its business priorities following the complete response letter for Vyglxia. This should help refocus investor attention on the company's key value drivers, the analyst tells investors in a research note.

Morgan Stanley

Overweight

NULL

downgrade

$54 -> $26

2025-11-18

Reason

Morgan Stanley

Price Target

$54 -> $26

2025-11-18

downgrade

Overweight

NULL

Reason

Morgan Stanley lowered the firm's price target on Biohaven to $26 from $54 and keeps an Overweight rating on the shares. After the company received a Complete Response Letter from the FDA regarding its NDA for Troriluzole in spinocerebellar ataxia, the firm removed Troriluzole and updated its model following Q3 results. The next catalyst for the stock is Opakalim Phase 2 data in major depressive disorder that is expected in Q4, the analyst tells investor

Citi

Buy

downgrade

$28 -> $14

2025-11-13

Reason

Citi

Price Target

$28 -> $14

2025-11-13

downgrade

Buy

Reason

Citi lowered the firm's price target on Biohaven to $14 from $28 and keeps a Buy rating on the shares. The firm cites the complete response letter in spinocerebellar ataxia for the target cut. Citi remains cautious into Biohaven's upcoming Phase 3 depression data but says the recent equity raise alleviates a near-term financing overhang.

BTIG

Buy

downgrade

$33 -> $16

2025-11-06

Reason

BTIG

Price Target

$33 -> $16

2025-11-06

downgrade

Buy

Reason

BTIG lowered the firm's price target on Biohaven to $16 from $33 and keeps a Buy rating on the shares following Tuesday's announcement of the complete response letter for troriluzole in SCA. The CRL likely "ends a messy chapter" for the company in SCA, the analyst tells investors in a research note. The 60% R&D restructuring is hard to model without details, so the calculated $16 TP may be a little low pending a better read on cuts, the firm added.

Valuation Metrics

The current forward P/E ratio for Biohaven Ltd (BHVN.N) is -2.66, compared to its 5-year average forward P/E of -4.32. For a more detailed relative valuation and DCF analysis to assess Biohaven Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.32

Current PE

-2.66

Overvalued PE

-2.63

Undervalued PE

-6.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.48

Current EV/EBITDA

-3.23

Overvalued EV/EBITDA

-0.71

Undervalued EV/EBITDA

-6.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

65132.58

Current PS

0.00

Overvalued PS

291451.71

Undervalued PS

-161186.56

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 3226.99% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 3226.99% over the last month.

Sold

Bought

BHVN News & Events

Events Timeline

No data

News

9.0

12-11SeekingAlpha

Biohaven Rallies on Promising Early Data for Antibody Drug Conjugate Combination

9.0

12-11PRnewswire

Biohaven Presents BHV-1510 Clinical Data with 72.7% ORR at ESMO 2025

4.0

12-06NASDAQ.COM

Biohaven (BHVN) Price Target Reduced by 23.10% to $19.95

People Also Watch

Frequently Asked Questions

What is Biohaven Ltd (BHVN) stock price today?

The current price of BHVN is 11.28 USD — it has decreased -2.17 % in the last trading day.

What is Biohaven Ltd (BHVN)'s business?

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

What is the price predicton of BHVN Stock?

What is Biohaven Ltd (BHVN)'s revenue for the last quarter?

Biohaven Ltd revenue for the last quarter amounts to -169.38M USD, decreased -4.93 % YoY.

What is Biohaven Ltd (BHVN)'s earnings per share (EPS) for the last quarter?

Biohaven Ltd. EPS for the last quarter amounts to -145729000.00 USD, increased 2.71 % YoY.

What changes have occurred in the market's expectations for Biohaven Ltd (BHVN)'s fundamentals?

How many employees does Biohaven Ltd (BHVN). have?

Biohaven Ltd (BHVN) has 256 emplpoyees as of December 15 2025.

What is Biohaven Ltd (BHVN) market cap?

Today BHVN has the market capitalization of 1.46B USD.